164 related articles for article (PubMed ID: 15125588)
1. Influence of surfactants on the physical stability of solid lipid nanoparticle (SLN) formulations.
Uner M; Wissing SA; Yener G; Müller RH
Pharmazie; 2004 Apr; 59(4):331-2. PubMed ID: 15125588
[TBL] [Abstract][Full Text] [Related]
2. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure.
Kovacevic A; Savic S; Vuleta G; Müller RH; Keck CM
Int J Pharm; 2011 Mar; 406(1-2):163-72. PubMed ID: 21219990
[TBL] [Abstract][Full Text] [Related]
3. Influence of co-surfactants on crystallization and stability of solid lipid nanoparticles.
Salminen H; Helgason T; Aulbach S; Kristinsson B; Kristbergsson K; Weiss J
J Colloid Interface Sci; 2014 Jul; 426():256-63. PubMed ID: 24863791
[TBL] [Abstract][Full Text] [Related]
4. Stability of lipid excipients in solid lipid nanoparticles.
Radomska-Soukharev A
Adv Drug Deliv Rev; 2007 Jul; 59(6):411-8. PubMed ID: 17553589
[TBL] [Abstract][Full Text] [Related]
5. Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system.
Kalam MA; Sultana Y; Ali A; Aqil M; Mishra AK; Chuttani K
J Drug Target; 2010 Apr; 18(3):191-204. PubMed ID: 19839712
[TBL] [Abstract][Full Text] [Related]
6. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles.
Vivek K; Reddy H; Murthy RS
AAPS PharmSciTech; 2007 Oct; 8(4):E83. PubMed ID: 18181544
[TBL] [Abstract][Full Text] [Related]
7. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization.
Attama AA; Schicke BC; Paepenmüller T; Müller-Goymann CC
Eur J Pharm Biopharm; 2007 Aug; 67(1):48-57. PubMed ID: 17276663
[TBL] [Abstract][Full Text] [Related]
8. Physicochemical properties of lipid nanoparticles: effect of lipid and surfactant composition.
Martins S; Tho I; Ferreira DC; Souto EB; Brandl M
Drug Dev Ind Pharm; 2011 Jul; 37(7):815-24. PubMed ID: 21214488
[TBL] [Abstract][Full Text] [Related]
9. Physicochemical investigations on the structure of drug-free and drug-loaded solid lipid nanoparticles (SLN) by means of DSC and 1H NMR.
Zimmermann E; Souto EB; Müller RH
Pharmazie; 2005 Jul; 60(7):508-13. PubMed ID: 16076076
[TBL] [Abstract][Full Text] [Related]
10. Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN).
Helgason T; Awad TS; Kristbergsson K; McClements DJ; Weiss J
J Colloid Interface Sci; 2009 Jun; 334(1):75-81. PubMed ID: 19380149
[TBL] [Abstract][Full Text] [Related]
11. Chemical stability of lipid excipients in SLN-production of test formulations, characterisation and short-term stability.
Radomska-Soukharev A; Müller RH
Pharmazie; 2006 May; 61(5):425-30. PubMed ID: 16724540
[TBL] [Abstract][Full Text] [Related]
12. The effect of a lipid composition and a surfactant on the characteristics of the solid lipid microspheres and nanospheres (SLM and SLN).
Sznitowska M; Wolska E; Baranska H; Cal K; Pietkiewicz J
Eur J Pharm Biopharm; 2017 Jan; 110():24-30. PubMed ID: 27815177
[TBL] [Abstract][Full Text] [Related]
13. Electrolyte- and pH-stabilities of aqueous solid lipid nanoparticle (SLN) dispersions in artificial gastrointestinal media.
Zimmermann E; Müller RH
Eur J Pharm Biopharm; 2001 Sep; 52(2):203-10. PubMed ID: 11522487
[TBL] [Abstract][Full Text] [Related]
14. Investigation of surface-modified solid lipid nanocontainers formulated with a heterolipid-templated homolipid.
Attama AA; Müller-Goymann CC
Int J Pharm; 2007 Apr; 334(1-2):179-89. PubMed ID: 17140752
[TBL] [Abstract][Full Text] [Related]
15. Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery.
Liu CH; Wu CT; Fang JY
Drug Dev Ind Pharm; 2010 Jul; 36(7):751-61. PubMed ID: 20136495
[TBL] [Abstract][Full Text] [Related]
16. Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles.
Martins S; Tho I; Souto E; Ferreira D; Brandl M
Eur J Pharm Sci; 2012 Apr; 45(5):613-23. PubMed ID: 22245538
[TBL] [Abstract][Full Text] [Related]
17. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for application of ascorbyl palmitate.
Uner M; Wissing SA; Yener G; Müller RH
Pharmazie; 2005 Aug; 60(8):577-82. PubMed ID: 16124399
[TBL] [Abstract][Full Text] [Related]
18. The influence of the crystallinity of lipid nanoparticles on their occlusive properties.
Wissing S; Müller R
Int J Pharm; 2002 Aug; 242(1-2):377-9. PubMed ID: 12176283
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical characterization of sildenafil-loaded solid lipid nanoparticle dispersions (SLN) for pulmonary application.
Paranjpe M; Finke JH; Richter C; Gothsch T; Kwade A; Büttgenbach S; Müller-Goymann CC
Int J Pharm; 2014 Dec; 476(1-2):41-9. PubMed ID: 25261709
[TBL] [Abstract][Full Text] [Related]
20. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)--effects of formulation parameters on physicochemical stability.
Teeranachaideekul V; Müller RH; Junyaprasert VB
Int J Pharm; 2007 Aug; 340(1-2):198-206. PubMed ID: 17482778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
